Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989503 | 0.79 | TNF (0.31) | TNFRIPK1 | |
| SCHEMBL2046247 | 0.77 | TNF (0.41) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL31289362 | 0.77 | TNF (0.41) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL489680 | 0.75 | CES2 (0.40) | — | |
| SCHEMBL9847889 | 0.73 | TNF (0.46) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL8755324 | 0.72 | TNF (0.38) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL725111 | 0.72 | TNF (0.38) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL22151102 | 0.70 | USP2 (0.34) | — | |
| Nitrogen SCHEMBL28690307 | 0.70 | TNF (0.37) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL4466075 | 0.70 | RAB9A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| WO-2021041997-A1 | CO-POTENTIATORS FOR THERAPY OF CYSTIC FIBROSIS CAUSED BY MINIMAL FUNCTION CFTR MUTANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-04 | — | — | WO | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | claimed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | claimed |
| CN-102532198-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC | 2012-07-04 | — | — | CN | claimed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | claimed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | claimed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | claimed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | claimed |
| CN-101489564-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC (US) | 2009-07-22 | — | — | CN | claimed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | claimed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | claimed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-11845762-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-114369082-B | Pyridine substituted spiro compounds and application thereof in preparation of anti-plant virus agent | 贵州大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-111712496-B | Compounds and compositions as bromodomain protein inhibitors | 贝达药业股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021041997-A1 | CO-POTENTIATORS FOR THERAPY OF CYSTIC FIBROSIS CAUSED BY MINIMAL FUNCTION CFTR MUTANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| EP-3719017-A2 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | Betta Pharmaceuticals Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | disclosed |
| EP-3071560-B1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-9783523-B2 | N-acylimino heterocyclic compounds | BASF SE (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| CN-102532198-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009067541-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466034-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | TNF 3880/4885RIPK1 319/4885HTR2A 3847/4885 |
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | TNF 3610/4885RIPK1 445/4885HTR2A 4569/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | TNF 3610/4885RIPK1 445/4885HTR2A 4569/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | TNF 3610/4885RIPK1 445/4885HTR2A 4569/4885 |
| US-20230022091-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | TNF 3880/4885RIPK1 319/4885HTR2A 3847/4885 |
| US-11845762-B2 | Compound functioning as bromodomain protein inhibitor, and composition | BRD4, BRD1, BRD2 | TNF 3880/4885RIPK1 319/4885HTR2A 3847/4885 |
| US-20200385408-A1 | COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION | BRD4, BRD1, BRD2 | TNF 3880/4885RIPK1 319/4885HTR2A 3847/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | TNF 3283/4885RIPK1 1769/4885HTR2A 4110/4885 |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | CBR3, C5, ALOX5 | TNF 4478/4885RIPK1 2057/4885HTR2A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.